See more : Dispensa Group Plc (DISP.L) Income Statement Analysis – Financial Results
Complete financial analysis of NightHawk Biosciences, Inc. (NHWK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NightHawk Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Crucible Acquisition Corporation (CRUBW) Income Statement Analysis – Financial Results
- Australian Clinical Labs Limited (ACL.AX) Income Statement Analysis – Financial Results
- Basic-Fit N.V. (BFIT.AS) Income Statement Analysis – Financial Results
- PT Yulie Sekuritas Indonesia Tbk (YULE.JK) Income Statement Analysis – Financial Results
- Inter & Co, Inc. (INTR) Income Statement Analysis – Financial Results
NightHawk Biosciences, Inc. (NHWK)
About NightHawk Biosciences, Inc.
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.98M | 2.11M | 2.95M | 3.05M | 5.79M | 1.52M | 341.64K | 0.00 | 0.00 | 0.00 | 3.11K | 187.79K |
| Cost of Revenue | 6.40M | 691.48K | 12.94M | 13.01M | 16.23M | 8.27M | 9.33M | 116.00K | 5.25M | 1.40M | 253.19K | 0.00 |
| Gross Profit | -420.03K | 1.42M | -9.99M | -9.96M | -10.44M | -6.75M | -8.99M | -116.00K | -5.25M | -1.40M | -250.08K | 187.79K |
| Gross Profit Ratio | -7.02% | 67.27% | -338.91% | -326.80% | -180.18% | -443.94% | -2,631.12% | 0.00% | 0.00% | 0.00% | -8,041.13% | 100.00% |
| Research & Development | 23.46M | 18.82M | 12.94M | 13.01M | 16.23M | 8.27M | 9.33M | 2.60M | 2.86M | 2.74M | 902.94K | 1.25M |
| General & Administrative | 21.13M | 16.83M | 14.93M | 9.43M | 7.03M | 6.37B | 4.14M | 4.36M | 3.98M | 2.43B | 1.18M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.36B | 0.00 | 14.07M | 5.35M | -2.43B | 5.92K | 0.00 |
| SG&A | 21.13M | 16.83M | 14.93M | 9.43M | 7.03M | 6.37M | 4.14M | 18.43M | 9.33M | 3.83M | 1.44M | 976.00K |
| Other Expenses | 628.45K | -965.82K | 188.42K | -25.56K | 117.78K | 224.29M | 670.78K | 14.07M | 5.35M | 1.40B | 0.00 | 0.00 |
| Operating Expenses | 45.22M | 35.65M | 27.87M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Cost & Expenses | 51.62M | 35.65M | 27.87M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Interest Income | 987.25K | 815.32K | 566.72K | 431.82K | 265.75K | 22.17K | 31.14K | 66.00K | 40.57K | 10.07K | 2.00 | 517.00 |
| Interest Expense | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 549.40K | 364.00K | 73.35K | 79.12K | 101.09K | 63.17K |
| Depreciation & Amortization | 4.93M | 4.35M | 3.74M | 2.70M | 237.32K | 134.08K | 132.08K | 116.00K | 66.90K | 6.35K | 2.59K | 624.00 |
| EBITDA | -40.76M | -31.07M | -22.38M | -18.05M | -16.73M | -12.96M | -12.29M | -20.84M | -12.08M | -6.55M | -2.34M | -2.03M |
| EBITDA Ratio | -681.44% | -1,470.53% | -759.20% | -591.82% | -288.77% | -852.82% | -3,598.29% | 0.00% | 0.00% | 0.00% | -75,243.99% | -1,082.96% |
| Operating Income | -45.69M | -35.42M | -26.12M | -20.75M | -17.96M | -13.34M | -13.13M | -21.02M | -12.19M | -6.56M | -2.34M | -2.03M |
| Operating Income Ratio | -763.90% | -1,676.40% | -886.18% | -680.39% | -309.99% | -877.85% | -3,842.41% | 0.00% | 0.00% | 0.00% | -75,327.23% | -1,083.57% |
| Total Other Income/Expenses | -1.51M | -4.38M | -1.46M | -944.02K | -112.40K | -700.85K | 152.52K | -100.00K | -56.00K | -45.22K | -108.34K | -64.18K |
| Income Before Tax | -47.15M | -35.55M | -26.38M | -20.34M | -17.58M | -13.22M | -12.97M | -21.12M | -12.24M | -6.61M | -2.45M | -2.10M |
| Income Before Tax Ratio | -788.35% | -1,682.44% | -894.90% | -667.07% | -303.37% | -869.73% | -3,797.77% | 0.00% | 0.00% | 0.00% | -78,810.87% | -1,117.75% |
| Income Tax Expense | -3.29M | -145.97K | 1.31M | 45.18K | -985.49K | -809.54K | 819.34K | -463.00K | -381.04K | 2.18M | 70.27K | 69.08K |
| Net Income | -43.86M | -35.40M | -27.69M | -20.38M | -15.73M | -11.84M | -12.57M | -20.30M | -11.79M | -8.71M | -2.42M | -2.10M |
| Net Income Ratio | -733.36% | -1,675.54% | -939.43% | -668.55% | -271.56% | -779.09% | -3,680.44% | 0.00% | 0.00% | 0.00% | -77,819.94% | -1,120.89% |
| EPS | -1.72 | -1.42 | -1.73 | -4.29 | -6.30 | -21.56 | -50.05 | -177.23 | -127.84 | -162.73 | -92.49 | -79.03 |
| EPS Diluted | -1.71 | -1.42 | -1.73 | -4.29 | -6.30 | -21.56 | -50.05 | -174.92 | -126.18 | -160.61 | -91.28 | -79.03 |
| Weighted Avg Shares Out | 25.55M | 24.87M | 15.98M | 4.75M | 2.50M | 549.33K | 251.23K | 114.51K | 92.21K | 53.53K | 26.17K | 26.63K |
| Weighted Avg Shares Out (Dil) | 25.61M | 24.91M | 15.98M | 4.75M | 2.50M | 549.33K | 251.23K | 116.02K | 93.43K | 54.24K | 26.51K | 26.63K |
Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University
Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium
Scorpius Holdings, Inc. Announces Closing of Public Offering
Scorpius Holdings, Inc. Announces Pricing of Public Offering
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today
NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note
NightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
Source: https://incomestatements.info
Category: Stock Reports